Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of Neuromuscular Blockade with Neostigmine
NCT04048655Active, not recruiting
- Sponsor
- Tampere University Hospital
- Start
- Apr 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of neostigmine in neuromuscular blockade (NMB), sponsored by Tampere University Hospital. Primary endpoint: Incidence of postrecovery relaxation at 30 minutes. Started Apr 2020; status: active, not recruiting.
02
Drugs
neostigmine
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04048655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048655.